Lilly Advances Candidates, Brings In Phase II Molecules To Quell Pipeline Worries
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
It was all about the pipeline during Eli Lilly’s fourth quarter earnings call, as company execs strove to convince analysts they’ve made progress in efforts to counter revenue losses from big-ticket products about to lose patent protection.
You may also be interested in...
FDA's Victoza Decision BalancedUnknown Cancer Risk Against Known FDAAA Measures
FDA’s approval of Novo Nordisk’s type 2 diabetes drug Victoza (liraglutide) was a bit surprising for an agency often seen as increasingly conservative, even given that the Jan. 25 decision came with extensive labeling, risk management and mandatory post-market studies focused on the cancer risk.
BMS, Lilly Reach Agreement To Co-Develop Erbitux Follow-On
During its fourth-quarter 2009 earnings call, Bristol also urged investors to show patience with disappointing sales of Onglyza.
FDA Clears Victoza, But Warnings And More Studies Pose Hurdles
Liraglutide's US approval comes with a black box warning for a thyroid cancer risk and hefty post-marketing requirements.